Novo Nordisk (NVO) stock shed over 21% on Tuesday after the Danish pharmaceutical giant slashed its guidance for the second time this year, leaving investors questioning whether the obesity drug pioneer has lost its edge or presents a compelling value opportunity.
Novo Nordisk’s latest guidance cut was brutal. Full-year sales growth expectations dropped to 8%-14% from the previously forecasted 13%-21%, while operating profit growth was reduced to 10%-16% versus prior estimates of 16%-24%. This marks the second guidance cut in just three months, signaling deeper structural challenges than initially anticipated.
